SCHEMBL5828956

SCHEMBL5828956

CC(C)(N)CCCC(N)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.54
NOS2 P35228 6/20 0.48
NOS1 P29475 5/20 0.48
NOS3 P29474 4/20 0.48
CYP2C19 P33261 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ARG2 P78540 4/20 0.48
ARG1 P05089 3/20 0.48
CYP1A2 P05177 3/20 0.47
TSHR P16473 2/20 0.47
CYP3A4 P08684 1/20 0.47
GLA P06280 1/20 0.47
NFKB1 P19838 1/20 0.47
APEX1 P27695 1/20 0.47
GRM8 O00222 1/20 0.46
GRM6 O15303 1/20 0.46
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIK1 P39086 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472931 1.00 GSR (0.54) GSRNOS2NOS1NOS3CYP2C19
Hydrochloric Acid SCHEMBL15372840 0.98 GSR (0.52) GSRNOS2NOS1NOS3CYP2C19
Hydrochloric Acid SCHEMBL15372842 0.98 GSR (0.52) GSRNOS2NOS1NOS3CYP2C19
Hydrochloric Acid SCHEMBL7130280 0.98 GSR (0.52) GSRNOS2NOS1NOS3CYP2C19
SCHEMBL21861898 0.87 GSR (0.54) GSRNOS2NOS1NOS3CYP2C19
SCHEMBL16497780 0.84 GSR (0.56) GSRNOS2NOS1NOS3CYP2C19
SCHEMBL10052913 0.84 GSR (0.56) GSRNOS2NOS1NOS3CYP2C19
SCHEMBL10052915 0.84 GSR (0.56) GSRNOS2NOS1NOS3CYP2C19
SCHEMBL19232133 0.83 GSR (0.55) GSRNOS2NOS1NOS3CYP2C19
Ammonia Solution, Strong SCHEMBL28728275 0.83 GSR (0.54) GSRNOS2NOS1NOS3CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11680088-B2 Bioactive peptides derived from snakes UNIVERSITEIT LEIDEN (NL) 2023-06-20 US claimed
US-20040054216-A1 Method for producing lysine derivative AJINOMOTO CO., INC. (JP) 2004-03-18 US claimed
US-6664412-B2 Protecting amino group or amino group and carboxyl group of optically active 2-amino-6-methyl-6-nitroheptanoic acid with protecting group, reducing nitro group to synthesize 6,6-dimethyllysine and reacting this with acetic acid AJINOMOTO CO., INC. (JP) 2003-12-16 US claimed
US-20030105351-A1 Method for producing lysine derivative AJINOMOTO CO. INC (JP) 2003-06-05 US claimed
US-20020042537-A1 Method for producing lysine derivative AJINOMOTO CO., INC. (JP) 2002-04-11 US claimed
EP-1179599-A2 Method for producing lysine derivative Ajinomoto Co., Inc. (JP) 2002-02-13 EP claimed
EP-4681719-A2 XANTHINE OXIDASE INHIBITOR FORMULATIONS XORTX Therapeutics Inc. (CA) 2026-01-21 EP disclosed
EP-3915565-B1 XANTHINE OXIDASE INHIBITOR FORMULATIONS XORTX THERAPEUTICS INC (CA) 2025-09-10 EP disclosed
EP-4568704-A1 XANTHINE OXIDASE INHIBITOR FORMULATIONS XORTX Therapeutics Inc. (CA) 2025-06-18 EP disclosed
US-12037372-B2 Bioactive peptides derived from snakes UNIVERSITEIT LEIDEN (NL) 2024-07-16 US disclosed
WO-2024033705-A1 XANTHINE OXIDASE INHIBITOR FORMULATIONS XORTX THERAPEUTICS, INC. (CA) 2024-02-15 WO disclosed
US-20230391839-A1 BIOACTIVE PEPTIDES DERIVED FROM SNAKES UNIV LEIDEN (NL) 2023-12-07 US disclosed
US-11680088-B2 Bioactive peptides derived from snakes UNIVERSITEIT LEIDEN (NL) 2023-06-20 US disclosed
US-20020042537-A1 Method for producing lysine derivative AJINOMOTO CO., INC. (JP) 2002-04-11 US disclosed
US-20020042537-A1 Method for producing lysine derivative AJINOMOTO CO., INC. (JP) 2002-04-11 US disclosed
EP-1179599-A2 Method for producing lysine derivative Ajinomoto Co., Inc. (JP) 2002-02-13 EP disclosed
EP-1179599-A2 Method for producing lysine derivative Ajinomoto Co., Inc. (JP) 2002-02-13 EP disclosed
US-20020016366-A1 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparation thereof and use thereof DEGUSSA AG (DE) 2002-02-07 US disclosed
US-20020016366-A1 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparation thereof and use thereof DEGUSSA AG (DE) 2002-02-07 US disclosed
WO-2001083423-A2 2,6-DIAMINO-6-METHYL-HEPTANOIC ACID AND DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF DEGUSSA AG (DE) 2001-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105351-A1 Method for producing lysine derivative JMJD6, SIRT6, KDM6A GSR 4367/4885NOS2 106/4885NOS1 108/4885
US-20040054216-A1 Method for producing lysine derivative JMJD6, SIRT6, KDM6A GSR 4367/4885NOS2 106/4885NOS1 108/4885
US-20020016366-A1 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparation thereof and use thereof CYP2D6, CYP2B6, CYP2A6 GSR 4806/4885NOS2 2895/4885NOS1 2390/4885
US-20020042537-A1 Method for producing lysine derivative JMJD6, SIRT6, KDM6A GSR 4367/4885NOS2 106/4885NOS1 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.